RELIBIO: Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis
Dupilumab's* efficacy and safety in severe CRSwNP was established in the LIBERTY NP SINUS-24 and SINUS-52 randomized, double-blind, placebo-controlled phase 3 trials, and is reflected in the approved SmPC.1,2
As real-world context to this robust RCT evidence, the observational RELIBIO study** provides additional insight into clinical effectiveness, treatment response, and switching patterns among 360 patients with severe CRSwNP treated with dupilumab (n=53), omalizumab (n=65) and mepolizumab (n=242) in routine Belgian clinical practice.3
SINUS-24/SINUS-52 Demonstrated Reduced Need for Surgery and Oral Corticosteroids — Dupilumab Real-World Data Reinforces with 100% Reduction in the First Year of Treatment in Patients with Severe Uncontrolled CRSwNP
This Italian monocentric study (De Corso et al., 2022) evaluated the real-life effectiveness of dupilumab over the first year of treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (N=57).2 The results from this real-life observational study reinforces the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and both the study design and results are consistent with the approved SmPC.1,2,3
Chronic Rhinosinusitis with Nasal Polyps: The Interplay of Type 2 Inflammation and Smell Loss
Bevestig uw status
Bevestig uw status
Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal
speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een ljst met
evenementen en tools en diensten voor uw dagelijkse praktik.